Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VPS53 antisense RNA 1 (VPS53-AS1) is a long non-coding RNA transcribed from the antisense strand of the VPS53 locus. Long non-coding antisense RNAs, such as VPS53-AS1, typically regulate the expression of their sense (protein-coding) genes through a range of mechanisms including altering chromatin structure, forming RNA duplexes to affect mRNA stability, and interacting with chromatin-modifying enzymes[5]. While many antisense lncRNAs have prominent roles in cancer, either promoting or suppressing tumorigenesis, there are currently no published studies that directly implicate VPS53-AS1 in specific disease processes. Its biological significance may be inferred from mechanisms established for other antisense lncRNAs, such as involvement in transcriptional regulation, epigenetic modification, and post-transcriptional gene silencing[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VPS53 antisense RNA 1 (VPS53-AS1).